Any findings
regarding objectives 2 and 3 - Other effects of HGH therapy and
Physical and social characteristics of patient population should
contain a caveat noting that there was no indentified control group
with comparable characteristics to the patient population prior to
HGH therapy.
Inventory as of this Action
Requested
Previously Approved
12/31/1990
12/31/1990
6,895
0
0
2,543
0
0
0
0
0
THIS STUDY WILL LOCATE PAST
PITUITARY-DERIVED GROWTH HORMONE RECIPIENTS FOR AN EPIDEMIOLOGICAL
INVESTIGATION TO DETERMINE T OVERALL INCIDENCE OF CREUTZFELDT-JACOB
DISEASE AND OTHER POTENTIALLY INFECTIOUS, LONG-INCUBATION,
NEUROLOGICAL DISEASES. THE STUDY WILL AL ENABLE ASSESSMENT OF THE
POSSIBILITY OF OTHER MEDICAL COMPLICATIONS AN LONG-TERM OUTCOMES OF
TREATMENT.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.